Advancement in product development, accelerated market entry and exhibitions:

In 2024, Uniogen experienced an exceptional year marked by significant progress and innovations in research and development in the areas of oncology and new system development. Our R&D teams pushed boundaries, resulting in groundbreaking solutions that can be expected to set new standards for in vitro diagnostic field and enhance our future product portfolio. Collaborative efforts across departments accelerated development cycles and led to patent applications and advancements to strengthen our competitive edge. These achievements highlighted our dedication to delivering innovative solutions to our customers. As we close out this year, we remain focused on pushing the limits and laying the groundwork for continued innovation in the years to come.

AMPlify program by Business Finland in collaboration with Mayo Clinic:

Uniogen innovation in early cancer detection, starting with ovarian cancer, was selected to an accelerated market entry platform called AMPlify. Together with Mayo Clinic (USA) and Business Finland as organizers, Uniogen had the chance to meet clinical experts at Mayo clinic and present the unique GLYVAR^TM Ovarian assay. The assay under development is based on glycovariant determination technology and is currently available for research use. We are looking forward to seeing what this collaboration will lead to in the future.

Uniogen at exhibitions:

UPCON 2024

We presented our latest results regarding Upcon^TM nanoparticle stability studies, elevated performance in C.difficile and advanced multiplexing capabilities in B.pertussis lateral flow-based assays. The successful event enabled us to broaden our network of collaboration with research units involved in the study of upconverting nanoparticles.

ANALYTICA

Analytica gave us a further understanding of the latest instrumentation and research market developments, and we returned home with an insight into different products and their market strategies. The ability to understand where to position our products was enhanced and the event helped us to clarify our view of the market.

ESCMID 2024

At ESCMID 2024, our goal was to connect not only with our current distributors and partners, but also to engage with new and potential collaborators. The diagnostic industry is poised for significant changes in the coming years, bringing both challenges and opportunities. In such times, collaboration and strategic partnerships are essential to unlocking new possibilities. We are pleased with the progress we are making alongside our partners and look forward to continued growth together.

Medica 2024

This year at Medica we were focused on partnering and were happy to have our customer Lumito with us at the joint stand as an example of a well-performing partnership. Lumito uses technology based on Upcon^TM nanoparticles enabling autofluorescence free measurements. During the exhibition we were able to gain a lot of good contacts for our partnering portfolio e.g. for our GLYVAR^TM Ovarian assay, infectious diseases diagnostics, Upcon^TM detection technology, assay reagents and for our CDMO services. We also gained input and feedback to some of our latest developments. This year Medica had about 80 000 visitors and over 5 000 exhibitors from 72 different countries.